Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus RETEVMO.
CAPRELSA vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
300 mg orally once daily, with or without food.
160 mg orally twice daily
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category C
Category C
Kinase Inhibitor
Kinase Inhibitor